291 related articles for article (PubMed ID: 25481812)
21. Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes.
Abdelhafiz AH; Sinclair AJ
J Diabetes Complications; 2018 Apr; 32(4):444-450. PubMed ID: 29274807
[TBL] [Abstract][Full Text] [Related]
22. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott LJ; Spencer CM
Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
[TBL] [Abstract][Full Text] [Related]
23. Glycaemic control: a balancing act or a different approach?
Fava S
Curr Diabetes Rev; 2014 Mar; 10(2):124-30. PubMed ID: 24745817
[TBL] [Abstract][Full Text] [Related]
24. Management of the patient with advanced complications, functional decline, and persistent hyperglycemia.
Zettervall DK
Consult Pharm; 2010 Jun; 25 Suppl B():5-10. PubMed ID: 20726377
[TBL] [Abstract][Full Text] [Related]
25. Extent and Predictors of Poor Glycaemic Control among Elderly Pakistani Patients with Type 2 Diabetes Mellitus: A Multi-Centre Cross-Sectional Study.
Atif M; Saleem Q; Asghar S; Malik I; Ahmad N
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30658518
[No Abstract] [Full Text] [Related]
26. Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine.
Janka HU
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():35-41. PubMed ID: 18577155
[TBL] [Abstract][Full Text] [Related]
27. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
Heald AH; Livingston M; Malipatil N; Becher M; Craig J; Stedman M; Fryer AA
Diabetes Obes Metab; 2018 Jan; 20(1):185-194. PubMed ID: 28730750
[TBL] [Abstract][Full Text] [Related]
28. Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough?
Triplitt C
Consult Pharm; 2010 Jun; 25 Suppl B():19-27. PubMed ID: 20726379
[TBL] [Abstract][Full Text] [Related]
29. Severe hypoglycaemia in elderly patients with type 2 diabetes and coexistence of cardiovascular history.
Piątkiewicz P; Buraczewska-Leszczyńska B; Kuczerowski R; Bernat-Karpińska M; Rabijewski M; Kowrach M
Kardiol Pol; 2016; 74(8):779-785. PubMed ID: 27040016
[TBL] [Abstract][Full Text] [Related]
30. Clinical management of elderly patients with type 2 diabetes mellitus.
Pratley RE; Gilbert M
Postgrad Med; 2012 Jan; 124(1):133-43. PubMed ID: 22314123
[TBL] [Abstract][Full Text] [Related]
31. Increasing awareness of hypoglycaemia in patients with type 2 diabetes treated with oral agents.
Barnett AH; Brice R; Hanif W; James J; Langerman H
Curr Med Res Opin; 2013 Nov; 29(11):1503-13. PubMed ID: 23952328
[TBL] [Abstract][Full Text] [Related]
32. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.
Pratley RE; Rosenstock J; Heller SR; Sinclair A; Heine RJ; Kiljański J; Brusko CS; Duan R; Festa A
J Diabetes Sci Technol; 2018 Nov; 12(6):1184-1191. PubMed ID: 29893144
[TBL] [Abstract][Full Text] [Related]
33. Mismatch between ADA and AGS recommendations for glycated hemoglobin targets for older adults.
Tasci I; Safer U; Naharci I; Sonmez A
Prim Care Diabetes; 2018 Apr; 12(2):192-194. PubMed ID: 29396204
[TBL] [Abstract][Full Text] [Related]
34. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies.
Schernthaner G; Schernthaner-Reiter MH
Diabetologia; 2018 Jul; 61(7):1503-1516. PubMed ID: 29417185
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
36. Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes.
Detournay B; Simon D; Guillausseau PJ; Joly D; Verges B; Attali C; Clement O; Briand Y; Delaitre O
Diabetes Metab; 2012 Apr; 38(2):102-12. PubMed ID: 22252014
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of self-monitoring of blood glucose versus retrospective continuous glucose monitoring in improving glycaemic control in diabetic kidney disease patients.
Yeoh E; Lim BK; Fun S; Tong J; Yeoh LY; Sum CF; Subramaniam T; Lim SC
Nephrology (Carlton); 2018 Mar; 23(3):264-268. PubMed ID: 27933715
[TBL] [Abstract][Full Text] [Related]
39. Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.
Du YF; Ou HY; Beverly EA; Chiu CJ
Clin Interv Aging; 2014; 9():1963-80. PubMed ID: 25429208
[TBL] [Abstract][Full Text] [Related]
40. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
Halimi S; Raccah D; Schweizer A; Dejager S
Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
